In a recent study, bicalutamide plus abiraterone achieved a 19% clinical benefit rate in AR-positive advanced TNBC.40,41 This inconsistency may be due to tumor evolution and patient selection after multiline chemotherapy in our study; another possibility is that AR may only be a biomarker rather than a therapeutic target. Here, AR is linked to neoplasm.